Methods to identify compounds that modulate RAGE

Details Methods to identify compounds that modulate RAGE Methods to identify compounds that modulate RAGE

2005-06-21

2005-06-21

Kemmerer, Elizabeth (Department: 1647)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007100, C435S035000, C530S350000

Reexamination Certificate

active

06908741

ABSTRACT:
Provided are methods to detect of modulators of the Receptor for Advanced Glycated Endproducts (RAGE). The invention comprises a method for detection of RAGE modulators comprising: adsorbing a RAGE ligand onto a solid surface; adding a compound of interest and a protein comprising RAGE or fragment thereof, to the preadsorbed ligand; adding an antibody which binds to RAGE or fragment thereof and a secondary antibody which binds to the anti-RAGE antibody; measuring the secondary antibody bound to the anti-RAGE antibody; and comparing the amount of RAGE bound to the ligand in the presence of varying amounts of the compound of interest. In an embodiment, the fragment of RAGE is sRAGE. In one aspect, the invention use of compounds detected by the method for treatment of AGE-related syndromes including complications associated with diabetes, kidney failure, lupus nephritis or inflammatory lupus nephritis, amyloidoses, Alzheimer's disease, cancer, inflammation, and erectile dysfunction.

REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4356108 (1982-10-01), Schwab et al.
patent: 4873313 (1989-10-01), Crawford et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5939536 (1999-08-01), Gaugler et al.
patent: 6100098 (2000-08-01), Newkirk
patent: 6555340 (2003-04-01), Schmidt et al.
patent: WO 97/26913 (1997-07-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 97/39125 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO 99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/54485 (1999-10-01), None
patent: WO 00/20458 (2000-04-01), None
patent: WO 00/20621 (2000-04-01), None
Li, et al, 1996, PNAS, 93: 11047-11052.
Hollinger, et al, 1999, Cancer and Metastasis Reviews, 18: 411-419.
Winter, et al, 1993, Immunol. Today, 14(6): 243-246.
Iwahashi, et al, 1999, Mol. Immunol., 36: 1079-1091.
Murdoch and Finn, 2000, Blood, 15(95): 3032-3043.
Shaw, A., 1993, Accession No. AAA03574.
Wautier, et al, 2001, Diabetes Metab., 27: 535-542.
Neeper, et al, 1992, J.B.C., 267(21): 14998-15004.
Kislinger, T. et al., Nε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression,J. of Biological Chemistry, 274 (44): 31740-31749 (1999).
Schmidt, A.M. et al., Activation of Receptor for Advanced Glycation End Products: A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis,Circ. Res. 84:489-497 (1999).
PCT International Search Report mailed Nov. 13, 2002 for PCT/US01/17447; international filing date May 30, 2001.
Chitaley et al., “Antagonism of Rho-Kinase Stimulates Rat Penile Erection via a Nitric Oxide-Independent Pathway”Nature Medicine7:119-122 (2001).
Crall et al., “The Extramural and Intramural Coronary Arteries in Juvenile Diabetes Mellitus”Am. J. Med. 64:221-230 (1978).
Degenhardt et al., “Chemical Modification of Proteins by Methylglyoxal”Cell Mol. Biol., 44:1139-1145 (1998).
Dyer et al., “Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose”J. Biol. Chem., 266:11654-11660 (1991).
Dyer et al., “Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging”J. Clin. Invest., 91:2463-2469 (1993).
Hamby et al., “Reappraisal of the role of the diabetic State in Coronary Artery Disease”Chest, 2:251-257 (1976).
Hammes et al., “Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product Nε-(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations”Diabetologia, 42:603-607 (1999).
Hoffman et al., “RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides”Cell, 97:889-901 (1999).
Hori et al, “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterian”J. Biol. Chem., 270:25752-761 (1995).
Huttunen et al., “Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways”J Biol Chem., 274:19919-24 (1999).
Johnson et al., “Antioxidant with Marked Lipid- and Glucose-Lowering Activity in Diabetic Rats and Mice”Diabetes. 42: 1179-86, (1993).
Kannel et al, “Diabetes and Cardiovascular Disease: The Framingham Study”J. Am. Med. Assoc., 241:2035-2038 (1979).
Kannel et al., “Diabetes and Glucose Tolerance as Risk Ractors for Cardiovascular Disease. The Framingham Study”Diab. Care, 2:120-126. (1979).
Kumar et al., “Rage at the Blood-Brain Barrier Mediated Neurovascular Dysfunction Caused by Amyloidβ1-40Peptide” Neurosci. Program, p141-#275.19 (2000).
Leder et al., “v-Ha-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid”Proc. Natl. Acad. Sci., 87:9178-9182 (1990).
Li et al., “Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products”J. Biol. Chem., 272:16498-16506 (1997).
Li et al., ,“Sp1-Binding Elements in the Promoter of RAGE Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells”J. Biol. Chem., 273:30870-30878 (1998).
Lugering et al., “The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function”Eur. J. Clin. Invest., 25:659-664 (1995).
Miyata et al., “β2-Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis”J. Clin. Invest., 92:1243-1252 (1993).
Miyata et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β2Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway”J. Clin. Invest., 98:1088-1094 (1996).
Needleman and Wunsch, “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”J. Mol. Biol. 48:443-453 (1970).
Neeper et al., “Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins”J. Biol. Chem., 267:14998-15004 (1992).
Park et al., “Suppression of Accelerated Diabetic Atherosclerosis by the Soluble Receptor for Advanced Glycation Endproducts”Nature Med., 4:1025-1031 (1998).
Parkkinen et al., “Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides”J. Biol. Chem. 268:19726-19738 (1993).
Pearson and Lipman, “Improved Tools for Biological Sequence Comparison”Proc. Natl. Acad. Sci.(USA), 85:2444-2448 (1988).
Pyorala et al., “Diabetes and Atherosclerosis: an Epidemiologic View”Diab. Metab. Rev., 3:463-524 (1987).
Rammes et al., “Myeloid-Related Protein (MRP) 8 and MRP14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulinp-Dependent Pathway”J. Biol. Chem., 272:9496-9502 (1997).
Rauvala et al., “Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons”J. Biol. Chem., 262:16625-16635 (1987).
Reddy et al., “Nε-(Carboxymedthyl)Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins”Biochem., 34:10872-10878 (1995).
Ritthaler et al, “Expression of Receptors for Advanced Glycation End Products in Peripheral Occlusive Vascular Disease,”Amer. J. Path., 146:688-694 (1995).
Robertson, et al., “Atherosclerosis in Persons with Hyp

Affiliated with

Also associated with

Rating

Methods to identify compounds that modulate RAGE does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to identify compounds that modulate RAGE, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify compounds that modulate RAGE will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3475291